澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - lixisenatide -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - teriflunomide -

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - neisseria meningitidis group a polysaccharide 50ug; neisseria meningitidis group c polysaccharide 50ug; neisseria meningitidis group w135 polysaccharide 50ug; neisseria meningitidis group y polysaccharide 50ug - injection with diluent - 0.5 ml - active: neisseria meningitidis group a polysaccharide 50ug neisseria meningitidis group c polysaccharide 50ug neisseria meningitidis group w135 polysaccharide 50ug neisseria meningitidis group y polysaccharide 50ug excipient: lactose monohydrate sodium chloride purified water - menomune® acyw-135 is indicated for active immunisation of adults and children older than 2 years against disease caused by neisseria meningitidis groups a, c, y and w-135, the major manifestation being meningococcal meningitis. vaccination may be considered for the following individuals: · travellers to countries recognised as having highly endemic or epidemic disease. · control of epidemics of infection caused by neisseria meningitidis groups a, c, y and w-135 in confined communities. · individuals at particular high risk of acquiring meningococcal infection, including persons with anatomic or functional asplenia. · close contacts of persons with meningococcal disease due to groups a, c, y and w-135, as an adjunct to appropriate chemoprophylaxis.

新加坡 - 英文 - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - inactivated poliomyelitis virus type 1 (mahoney); inactivated poliomyelitis virus type 2 (mef-1); inactivated poliomyelitis virus type 3 (saukett) - injection - 8 d.u. - inactivated poliomyelitis virus type 1 (mahoney) 40 d.u./0.5 ml; inactivated poliomyelitis virus type 2 (mef-1) 8 d.u./0.5 ml; inactivated poliomyelitis virus type 3 (saukett) 32 d.u./0.5 ml

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b );  ; influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275);  ; influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 );   - solution for injection - 0.5 ml - active: influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b )   influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275)   influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 )   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin potassium chloride sodium chloride water for injection - vaxigrip is indicated for the prevention of influenza caused by influenza virus types a and b in adults and children aged 6 months and over.

菲律宾 - 英文 - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: sanofi pasteur, inc. - meningococcal (groups a, polysaccharide diphtheria toxoid conjugate vaccine - solution for im injection - 4mcg; 4mcg; 4mcg; 4mcg; 48mcg

菲律宾 - 英文 - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: sanofi pasteur, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) 2023 southern hemisphere strain - suspension for injection (im) - formulation: each dose (0.5 ml) contains the following influenza strains*: a/sydney/5/2021 (h1n1) pdm09-like virus (a/sydney/5/2021, san-013) 15 μg of ha** a/darwin/9/2021 (h3n2)-like virus (a/darwin/9/2021, ivr-228) 15 μg of ha** b/austria/1359417/2021 (b/victoria lineage)-like virus (b/michigan/01/2021, wild type) 15 μg of ha** b/phuket/3073/2013 (b/yamagata lineage)-like virus (b/phuket/3073/2013, wild type) 15 μg of ha** *propagated in fertilized hen's eggs from healthy chicken flocks **haemagglutinin